JCR Pharmaceuticals Co., Ltd. (JP:4552)
:4552
Want to see JP:4552 full AI Analyst Report?
Top Page
JCR Pharmaceuticals Co., Ltd.
(4552)
Select Model
Select Model
Rating:46Neutral
Price Target:
¥440.00
▼(-38.20% Downside)
Action:Reiterated
Date:05/15/26
The score is weighed down primarily by weak financial quality driven by recent negative operating/free cash flow and higher leverage, despite the FY2026 revenue rebound. Technicals are also soft with the stock trading below key moving averages and negative momentum signals. Valuation further pressures the score due to an extremely high P/E, partially offset by a solid dividend yield.
Positive Factors
Niche specialty pharma focus
JCR's focus on rare-disease biologics and advanced drug delivery creates structural barriers: long development cycles, specialized regulatory pathways, and high switching costs for clinicians. Its contract manufacturing capabilities diversify revenue and leverage factory scale over the medium term.
Negative Factors
Negative operating and free cash flow
Sustained negative operating and free cash flow undermines the firm's ability to self-fund R&D, capex, and working capital. Over a 2–6 month horizon this elevates refinancing and execution risk, increasing dependence on external financing and potentially constraining strategic initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Niche specialty pharma focus
JCR's focus on rare-disease biologics and advanced drug delivery creates structural barriers: long development cycles, specialized regulatory pathways, and high switching costs for clinicians. Its contract manufacturing capabilities diversify revenue and leverage factory scale over the medium term.
Read all positive factors
JCR Pharmaceuticals Co., Ltd. (4552) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥55.56B
Dividend Yield2.71%
Average Volume (3M)578.69K
Price to Earnings (P/E)25.1
Beta (1Y)0.88
Revenue Growth21.91%
EPS GrowthN/A
CountryJP
Employees934
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)-45.01
Shares Outstanding129,686,310
10 Day Avg. Volume668,090
30 Day Avg. Volume578,686
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)1.48
Price to Sales (P/S)1.72
P/FCF Ratio-5.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥564.00Price Target Upside-20.79% Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)1.64
Revenue Forecast (FY)¥43.86B
JCR Pharmaceuticals Co., Ltd. Business Overview & Revenue Model
Company Description
JCR Pharmaceuticals Co., Ltd. is a specialized pharmaceutical firm primarily engaged in the creation, development, manufacturing, international trade, and distribution of medicinal products, regenerative therapies, and active pharmaceutical ingred...
How the Company Makes Money
JCR Pharmaceuticals primarily makes money by selling prescription pharmaceuticals that it develops and commercializes. Revenue is generated from product sales in its core therapeutic areas (including specialty/rare-disease treatments), typically v...
JCR Pharmaceuticals Co., Ltd. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
62
Positive
Cash Flow
25
Negative
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.50B | 40.32B | 33.07B | 42.87B | 34.34B | 51.08B |
| Gross Profit | 21.86B | 30.06B | 21.55B | 31.25B | 25.46B | 40.62B |
| EBITDA | -4.04B | 6.18B | -2.88B | 10.53B | 7.45B | 21.39B |
| Net Income | -5.50B | 2.18B | -4.76B | 5.51B | 3.77B | 14.51B |
Balance Sheet | ||||||
| Total Assets | 107.34B | 109.24B | 105.45B | 102.67B | 95.36B | 97.48B |
| Cash, Cash Equivalents and Short-Term Investments | 13.18B | 14.01B | 13.20B | 18.76B | 13.28B | 30.98B |
| Total Debt | 40.10B | 53.89B | 38.28B | 23.43B | 22.92B | 18.16B |
| Total Liabilities | 60.72B | 61.88B | 58.01B | 46.19B | 42.95B | 46.39B |
| Stockholders Equity | 46.26B | 46.94B | 47.04B | 56.18B | 52.16B | 50.88B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -11.56B | -15.37B | 7.79B | -13.15B | -2.04B |
| Operating Cash Flow | 0.00 | -135.00M | -5.49B | 9.31B | -5.50B | 9.29B |
| Investing Cash Flow | 0.00 | -12.50B | -9.87B | -2.69B | -15.00B | -3.25B |
| Financing Cash Flow | 0.00 | 13.30B | 9.74B | -2.03B | 1.95B | -2.18B |
JCR Pharmaceuticals Co., Ltd. Technical Analysis
Negative
712.00
Price Trends
531.02
Negative
582.62
Negative
614.26
Negative
Market Momentum
-24.29
Negative
28.38
Positive
16.07
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4552, the sentiment is Negative. The current price of 712 is above the 20-day moving average (MA) of 477.90, above the 50-day MA of 531.02, and above the 200-day MA of 614.26, indicating a bearish trend. The MACD of -24.29 indicates Negative momentum. The RSI at 28.38 is Positive, neither overbought nor oversold. The STOCH value of 16.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4552.
JCR Pharmaceuticals Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ¥1.26T | 17.24 | 4.27% | 2.33% | 3.20% | 43.05% | |
54 Neutral | ¥137.76B | -14.35 | ― | 2.18% | -10.48% | -1022.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥23.72B | -32.28 | ― | ― | -11.11% | -187.80% | |
47 Neutral | ¥90.89B | -8.92 | -19.31% | ― | 10.88% | -327.56% | |
46 Neutral | ¥55.56B | 25.14 | ― | 2.71% | 21.91% | ― | |
42 Neutral | ¥8.34B | -8.15 | ― | ― | -62.06% | 7.56% |
* Healthcare Sector Average
JP:4552
JCR Pharmaceuticals Co., Ltd.
449.00
-87.28
-16.28%
JP:4151
Kyowa Kirin Co
2,400.50
-34.54
-1.42%
JP:4565
Sosei Group
983.00
63.00
6.85%
JP:4974
Takara Bio Inc.
1,144.00
358.00
45.55%
JP:7774
Japan Tissue Engineering Co., Ltd.
584.00
-27.00
-4.42%
JP:7776
CellSeed Inc.
213.00
-302.00
-58.64%
JCR Pharmaceuticals Co., Ltd. Corporate Events
JCR Pharmaceuticals Corrects Q1 FY2025 Results While Maintaining Full-Year Profit Outlook
May 13, 2026
JCR Pharmaceuticals has issued a partial correction to its previously disclosed consolidated financial results for the three months ended June 30, 2025, after identifying errors in the original document. The company stated that certain numerical f...
JCR Pharmaceuticals Issues Partial Corrections to FY2024 Consolidated Results Amid Challenging Year
May 13, 2026
JCR Pharmaceuticals Co., Ltd., a global specialty drugmaker, focuses on rare diseases and complex conditions with a portfolio that includes treatments for growth disorders, Hunter and Fabry diseases, acute graft-versus-host disease, and renal anem...
JCR Pharmaceuticals Corrects Interim Results but Confirms FY2025 Outlook and Dividend Plan
May 13, 2026
JCR Pharmaceuticals Co., Ltd., a Japan-based specialty drugmaker listed on the Tokyo Stock Exchange, develops and commercializes therapies for rare diseases and other difficult-to-treat conditions. Its portfolio spans approved treatments for growt...
JCR Pharmaceuticals Revises Past Financial Results After Accounting Error Review
May 13, 2026
JCR Pharmaceuticals has announced partial corrections to previously disclosed consolidated financial results after identifying double-counted construction-in-progress assets and inventory expenses that had already been recognized. The company plan...
JCR Pharmaceuticals Corrects Nine-Month FY2025 Earnings Disclosure
May 13, 2026
JCR Pharmaceuticals, a Japan-based specialty drug maker focused on rare diseases and advanced biologic therapies, is leveraging its proprietary technologies and expanding its footprint across major global markets including the U.S. and Europe. Its...
JCR Pharmaceuticals Issues Cautious FY2025 Results Briefing Notice
May 13, 2026
JCR Pharmaceuticals released materials for its FY2025 results briefing session, outlining financial data and development progress, while emphasizing that the figures are rounded and may contain minor numerical discrepancies. The company stressed t...
JCR Pharmaceuticals Returns to Profit but Warns of Earnings Drop Amid Sales Growth
May 13, 2026
JCR Pharmaceuticals reported a strong turnaround for the fiscal year ended March 31, 2026, with consolidated net sales rising 21.9% to ¥40.3 billion and a swing back to profitability, posting ¥2.18 billion in profit attributable to owner...
JCR Pharmaceuticals Raises Earnings Outlook on Firm Sales and FX Gains
May 11, 2026
JCR Pharmaceuticals has upgraded its full-year earnings outlook for the fiscal year ended March 31, 2026, citing firm product sales and improved profitability. The company now expects net sales of ¥40.3 billion, operating profit of ¥0.5 ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.